CHRO — Chromocell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.61m
- $3.84m
Annual cashflow statement for Chromocell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.661 | -0.595 | -2.46 | -7.38 |
| Non-Cash Items | 0 | -0.242 | 0.251 | 4.15 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -2.97 | -0.756 | 0.641 | 2.25 |
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -3.63 | -1.59 | -1.57 | -0.981 |
| Financing Cash Flow Items | 3.38 | 1.59 | 1.22 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 3.63 | 1.59 | 1.62 | 1.02 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0 | 0.055 | 0.041 |